Global Generic Anti-cancer Injectables Market Growth (Status and Outlook) 2022-2028
SKU ID :LPI-21055819 | Published Date: 10-Jun-2022 | No. of pages: 104Description
As the global economy mends, the 2021 growth of Generic Anti-cancer Injectables will have significant change from previous year. According to our researcher latest study, the global Generic Anti-cancer Injectables market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Generic Anti-cancer Injectables market size will reach USD million in 2028, growing at a CAGR of % over the analysis period 2022-2028.
The United States Generic Anti-cancer Injectables market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Generic Anti-cancer Injectables market, reaching US$ million by the year 2028. As for the Europe Generic Anti-cancer Injectables landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main Generic Anti-cancer Injectables players cover Teva, Viatris, Biocon, and Amgen, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Generic Anti-cancer Injectables market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Bevacizuma
Rituximab
Herceptin
Paclitaxel
Others
Segmentation by channel: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Hospital
Retail
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Teva
Viatris
Biocon
Amgen
Sandoz (Novartis)
Pfizer
Qilu Pharmaceutical
Jiangsu Hansoh
CTTQ
Jiangsu Hengrui
CSPC
Innovent Biologics
The United States Generic Anti-cancer Injectables market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Generic Anti-cancer Injectables market, reaching US$ million by the year 2028. As for the Europe Generic Anti-cancer Injectables landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main Generic Anti-cancer Injectables players cover Teva, Viatris, Biocon, and Amgen, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Generic Anti-cancer Injectables market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Bevacizuma
Rituximab
Herceptin
Paclitaxel
Others
Segmentation by channel: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Hospital
Retail
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Teva
Viatris
Biocon
Amgen
Sandoz (Novartis)
Pfizer
Qilu Pharmaceutical
Jiangsu Hansoh
CTTQ
Jiangsu Hengrui
CSPC
Innovent Biologics
TOC
Tables & Figures
Companies
- PRICE
-
$3660$7320$5490Buy Now